A widely prescribed type of blood-pressure medication has been linked to a higher risk of worsening kidney disease in people with type 2 diabetes, raising questions about how hypertension should be managed when the kidneys are already vulnerable.
The concern centers on dihydropyridine calcium-channel blockers, or DCCBs, a common class of medication used when additional blood-pressure control is needed. In a large real-world study involving more than 31,000 people with type 2 diabetes, patients taking a DCCB alongside established kidney-protective therapies had a 33% higher relative risk of a major adverse kidney event than comparable patients receiving blood-pressure regimens without a DCCB.
The findings are important, but they do not establish that the medications directly caused kidney damage. The study was observational, and current diabetes guidelines have not advised patients to abandon calcium-channel blockers on the basis of this research. The original discussion of the finding can be found in Morning Overview’s report on blood-pressure medication and diabetic kidney disease.
Researchers Followed More Than 31,000 People With Type 2 Diabetes
The research examined health records from 31,031 adults with type 2 diabetes treated between 2016 and 2021 through Clalit Health Services. Every participant was already receiving both a renin-angiotensin system inhibitor and an SGLT2 inhibitor, two treatments commonly used to protect kidney function in appropriate patients with diabetic kidney disease.
Among the participants, 12,172, or about 39%, also received a dihydropyridine calcium-channel blocker. Another 18,859 received antihypertensive treatment that did not include this drug class. Patients were followed for a median of 1,260 days, or roughly three and a half years.
Researchers were particularly interested in major adverse kidney events. Their definition included either progression to kidney failure or a sustained decline of at least 40% in estimated glomerular filtration rate, commonly known as eGFR.
During follow-up, 482 participants experienced one of these kidney outcomes.
After researchers statistically adjusted for differences between the groups, DCCB treatment was associated with a hazard ratio of 1.33, corresponding to a 33% higher relative risk of a major adverse kidney event. The association remained significant when researchers accounted for the competing risk of death.
The peer-reviewed study can be read through PubMed’s record of the Kidney Medicine research.
Why Could a Drug That Lowers Blood Pressure Affect the Kidneys Differently?
At first glance, the finding seems counterintuitive.
High blood pressure itself is a major contributor to kidney damage. Controlling it is therefore one of the most important parts of managing diabetic kidney disease. How, then, could an effective blood-pressure medicine potentially be associated with worse kidney outcomes?
The answer may involve the difference between blood pressure measured in the arm and pressure inside the kidney’s microscopic filtering system.
Each kidney contains large numbers of filtering units called glomeruli. Blood enters and exits these structures through extremely small blood vessels. The pressure within those filtering units needs to remain carefully regulated.
Renin-angiotensin system inhibitors can lower pressure within the glomeruli in addition to reducing systemic blood pressure. SGLT2 inhibitors also have effects that can reduce intraglomerular pressure and slow the loss of kidney function. These mechanisms help explain why those treatments have become important parts of modern diabetic kidney care.
Researchers proposed that DCCBs could behave differently by preferentially dilating vessels carrying blood into the glomerulus. Under some circumstances, that could maintain or increase pressure inside the filtering structure even while the blood-pressure reading measured elsewhere in the body falls.
That explanation remains a hypothesis, however. The study was not designed to prove that this mechanism caused the observed kidney outcomes.
The 33% Figure Needs Careful Interpretation
The headline number is striking, but it needs context.
A 33% higher risk does not mean that 33% of patients taking these medications developed kidney failure.
It represents a relative difference in risk between the study groups after statistical adjustment. Across the entire population of more than 31,000 participants, 482 major adverse kidney events were recorded during follow-up.
The researchers also did not find a statistically significant increase in overall mortality associated with DCCB use, nor did they find a significant association with the study’s safety outcomes such as hospitalization or acute kidney injury.
This distinction matters because headlines describing a medication as “speeding kidney damage” can easily imply a level of certainty that the study does not provide.
The European Renal Association, which highlighted the research at its 2026 congress in Glasgow, specifically described the drugs as being associated with poorer kidney outcomes, rather than proven to cause them. Its detailed research announcement is available through the European Renal Association study release.
The Study Cannot Prove the Drugs Caused the Difference
This is the largest limitation of the research.
Participants were not randomly assigned to receive a calcium-channel blocker or an alternative. Researchers instead examined treatment that patients had already been prescribed.
That creates the possibility of residual confounding.
Before statistical adjustment, patients receiving DCCBs differed from the comparison group in several ways. They tended to have higher systolic blood pressure, lower kidney filtration rates, more albumin in the urine and a longer history of hypertension. Some also received different combinations and doses of other medications.
Those differences could mean that doctors were more likely to prescribe DCCBs to people whose hypertension or kidney disease was already more difficult to control.
Researchers used inverse probability weighting to make the groups more comparable, but statistical methods cannot guarantee that every meaningful difference has been eliminated.
The authors therefore concluded that prospective research and randomized controlled trials are needed before the association can be treated as causal.
Current Diabetes Guidelines Have Not Abandoned Calcium-Channel Blockers
Perhaps the most important context comes from current treatment guidelines.
The American Diabetes Association’s 2026 Standards of Care continue to emphasize blood-pressure control as fundamental to slowing chronic kidney disease. For people with diabetes, hypertension and significant albuminuria, an ACE inhibitor or angiotensin receptor blocker remains a preferred foundational treatment. SGLT2 inhibitors with proven benefit are also recommended for many people with type 2 diabetes and chronic kidney disease.
At the same time, the ADA still states that a dihydropyridine calcium-channel blocker or diuretic can be considered in appropriate circumstances, and many patients require multiple medications to reach their blood-pressure target.
The latest recommendations can be reviewed through the American Diabetes Association’s 2026 chronic kidney disease standards.
That means the new research should be viewed as a signal requiring further study, not as evidence that an established class of blood-pressure medicines has suddenly become inappropriate for everyone with diabetes.
Stopping Blood-Pressure Medication Could Carry Its Own Risk
The study also creates an important communication challenge.
Uncontrolled hypertension is itself a powerful driver of kidney disease and cardiovascular complications. A patient who abruptly stops a prescribed medication because of a new observational study could therefore exchange a possible long-term risk for a much more immediate and established one.
The researchers did not recommend that patients stop their medications.
Instead, the findings may eventually encourage clinicians to look more closely at the choice of second-line antihypertensive therapy in people who already have type 2 diabetes and are receiving modern kidney-protective treatment.
Kidney monitoring also remains important. Measures such as eGFR and urinary albumin can help clinicians assess whether kidney function is stable or changing over time. The ADA recommends regular kidney assessment in diabetes, with monitoring frequency increasing as chronic kidney disease becomes more advanced.
The Findings Could Refine Future Diabetic Kidney Treatment
The significance of the research lies less in declaring one drug class harmful and more in raising a new question about which combinations provide the best long-term kidney protection.
Diabetic kidney treatment has changed dramatically with the wider use of RAS inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists and newer mineralocorticoid receptor antagonists. As these treatments are increasingly combined, researchers need to understand how older blood-pressure medicines interact with that modern therapeutic foundation.
If randomized trials eventually reproduce the DCCB association, treatment strategies could change. Certain patients might receive alternative second-line medications or undergo closer kidney monitoring when a DCCB is necessary.
If better-controlled studies fail to reproduce the result, the association may turn out to reflect the fact that patients prescribed these drugs were already at greater risk.
For now, the distinction is critical: the research found an association, not proof of harm.
A common blood-pressure treatment has produced a signal strong enough to deserve serious investigation, but not strong enough to justify patients changing treatment without medical guidance. For millions of people living with both diabetes and hypertension, the next studies may help determine whether lowering blood pressure is only part of the equation and whether the specific way it is lowered matters just as much.
